Petition to the FDA to Ban the Gout Medication Febuxostat (Uloric)

June 21, 2018

View as PDF

View press release

Public Citizen petitioned the Food and Drug Administration (FDA) to ban the sale of the widely prescribed gout drug febuxostat (sold under the brand name Uloric) because use of the drug increases the risk of death compared with alternative therapies and there exist other effective medications that have been approved by the FDA for treatment of gout that have a lower risk of death.

June 21, 2018, FDA acknowledgment letter.